Commercial ExpansionFennec Pharmaceuticals is advancing its European commercial rollout with the acceptance of PEDMARQSI for use in Scotland and launches in Germany, England, and Wales.
Intellectual PropertyPEDMARK has IP protection until 2039 and orphan drug status until 2029, providing a competitive advantage in the market.
Market OpportunityPEDMARK represents a potential >$300M market opportunity in the US at the current pricing.